Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 9/20 | 0.48 |
| ▸ | PDE4A | P27815 | 7/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.48 |
| ▸ | GSK3B | P49841 | 6/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6120781 | 0.82 | PDE4D (0.50) | PDE4DPDE4APDE4BPDE4CALOX15 | |
| SCHEMBL6120083 | 0.82 | PDE4A (0.44) | PDE4DPDE4APDE4BPDE4CALOX15 | |
| SCHEMBL9204477 | 0.82 | KDM4E (0.54) | PDE4DPDE4APDE4BPDE4CGSK3B | |
| SCHEMBL8012403 | 0.82 | GSK3B (0.42) | PDE4DPDE4APDE4BPDE4CGSK3B | |
| SCHEMBL19214125 | 0.81 | PDE4D (0.40) | PDE4DPDE4APDE4BPDE4CALOX15 | |
| SCHEMBL9589309 | 0.80 | PDE4D (0.47) | PDE4DPDE4APDE4BPDE4CGSK3B | |
| SCHEMBL19318659 | 0.79 | GSK3B (0.56) | GSK3BPTPN1 | |
| SCHEMBL2297062 | 0.78 | NOTUM (0.51) | PDE4DPDE4APDE4BPDE4CALOX15 | |
| SCHEMBL17711366 | 0.78 | PDE4D (0.41) | PDE4DPDE4APDE4BPDE4CALOX15 | |
| SCHEMBL7859993 | 0.76 | TSHR (0.46) | GSK3BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| EP-3284741-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3284741-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-2640719-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-2640719-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| CN-105801390-A | Method for synthesizing 2,4-dibromo-3-difluoromethoxy acetophenone | 浙江中欣氟材股份有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105801390-A | Method for synthesizing 2,4-dibromo-3-difluoromethoxy acetophenone | 浙江中欣氟材股份有限公司 | 2016-07-27 | — | — | CN | disclosed |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9156823-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156823-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| EP-2640719-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012068234-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012068234-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PDE4D 3727/4885PDE4A 3099/4885PDE4B 3270/4885 |
| US-10344019-B2 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | PDE4D 3727/4885PDE4A 3099/4885PDE4B 3270/4885 |
| US-20150353529-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PDE4D 3727/4885PDE4A 3099/4885PDE4B 3270/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PDE4D 3727/4885PDE4A 3099/4885PDE4B 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.